Literature DB >> 19710673

Resolution of pansclerotic morphea after treatment with antithymocyte globulin.

Philip Song1, Christopher Gocke, Fredrick M Wigley, Francesco Boin.   

Abstract

BACKGROUND: A previously healthy 50-year-old man presented with thickening and hardening of the skin on his trunk, neck and upper extremities that had started after the appearance of a 5 cm web-like patch of blood vessels on his upper chest and progressed over 4 months. He also reported difficulties with swallowing and a 20 kg weight loss. INVESTIGATIONS: Physical examination, laboratory testing, including complete blood count, autoimmune serology for antiplatelet, antinuclear and extractable nuclear antibodies, direct antiglobulin test, incisional skin biopsy, bone-marrow biopsy, and MRI of the upper extremities. DIAGNOSIS: Pansclerotic morphea associated with red cell aplasia and immune-mediated thrombocytopenia. MANAGEMENT: Treatment with prednisone 60 mg per day and methotrexate 15 mg per week was started, but symptoms worsened. Methotrexate was replaced by pulsed intravenous methylprednisolone (1 g daily for 3 days), followed by mycophenolate mofetil started at 1 g per day and titrated up over 4 weeks to 3 g per day. Severe bicytopenia developed that did not improve with an 8-week washout of immunosuppressive agents. His fibrotic skin and hematologic conditions dramatically responded to antithymocyte globulin 40 mg/kg daily for 4 days, plus 10 mg/kg ciclosporin and methylprednisolone 1 mg/kg per day.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710673     DOI: 10.1038/nrrheum.2009.159

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  18 in total

Review 1.  [Efficacy of anti-thymocyte globulin and cyclosporin A combined therapy in aplastic anemia complicated with limited cutaneous systemic sclerosis].

Authors:  Eiichi Suematsu; Tomoya Miyamura; Kensaku Idutsu; Rumi Minami; Masahiro Yamamoto
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  2005-04

2.  Pansclerotic morphea of the head.

Authors:  Thomas Herzinger; Jörg Christoph Prinz; Martin Röcken
Journal:  Arch Dermatol       Date:  2008-01

Review 3.  Systemic sclerosis: current pathogenetic concepts and future prospects for targeted therapy.

Authors: 
Journal:  Lancet       Date:  1996-05-25       Impact factor: 79.321

4.  Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome.

Authors:  Stephen Rosenfeld; Dean Follmann; Olga Nunez; Neal S Young
Journal:  JAMA       Date:  2003-03-05       Impact factor: 56.272

5.  Anemia and scleroderma: frequency, causes, and marrow findings.

Authors:  M P Westerman; R C Martinez; T A Medsger; R S Totten; G P Rodnan
Journal:  Arch Intern Med       Date:  1968-07

Review 6.  Scleroderma and pseudo-scleroderma: uncommon presentations.

Authors:  Uwe-Frithjof Haustein
Journal:  Clin Dermatol       Date:  2005 Sep-Oct       Impact factor: 3.541

7.  Disabling pansclerotic morphea: clinical presentation in two adults.

Authors:  Sherry Henderson Maragh; Mark D P Davis; Alison J Bruce; Audrey M Nelson
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

8.  Disabling pansclerotic morphea of children.

Authors:  J L Diaz-Perez; S M Connolly; R K Winkelmann
Journal:  Arch Dermatol       Date:  1980-02

9.  Response of aplastic anaemia and scleroderma to cyclosporin.

Authors:  J A Tooze; J C Marsh; N Wickham; O L Duke; J Behrens; E C Gordon-Smith
Journal:  Br J Haematol       Date:  1993-12       Impact factor: 6.998

Review 10.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.

Authors:  M Mohty
Journal:  Leukemia       Date:  2007-04-05       Impact factor: 11.528

View more
  4 in total

1.  Generalized Morphea Coincident With Aplastic Anemia: A Case Report.

Authors:  Madhusudan R Tapdia; T T Favas; Vijaya Nath Mishra; Abhishek Pathak; Varun K Singh
Journal:  Cureus       Date:  2022-01-05

2.  Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort.

Authors:  Andrew Kim; Nicholas Marinkovich; Rebecca Vasquez; Heidi T Jacobe
Journal:  J Rheumatol       Date:  2013-12-01       Impact factor: 4.666

Review 3.  Overview of Juvenile localized scleroderma and its management.

Authors:  Suzanne C Li; Rong-Jun Zheng
Journal:  World J Pediatr       Date:  2019-11-30       Impact factor: 2.764

4.  An Unusual Case of Morphea in the Setting of Aplastic Anemia.

Authors:  Sierra Mastrantonio; Brian R Hinds; Jeremy A Schneider; Rachel Sennett; David G Cotter
Journal:  Cureus       Date:  2020-04-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.